CYCLOPHARM LIMITED — Board/Management Information 2016

Jul 13, 2016

==> picture [151 x 48] intentionally omitted <==

14 July 2016 The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

cyclo medica techne gas Cyclopharm Ltd ABN 74 116 931 250 Bldg 75 Business & Technology Park New Illawarra Road Lucas Heights NSW 2234 Australia POB 350 Menai Central NSW 2234 T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

Cyclopharm Strengthens Management Depth and Expands Clinical Expertise

Australian radiopharmaceutical company Cyclopharm Limited (ASX: CYC) is pleased to announce it has strengthened its management team with the appointment of Dr Michael Guo to the role of Clinical Program Director.

In that role, Dr Guo will be responsible for supervising Cyclopharm’s clinical trial programme, a key element of the Company’s growth strategy, including expanding clinical indications and applications for Technegas to include disease states such as Chronic Obstructive Pulmonary Disease (COPD), Asthma, Lung Cancer and Pulmonary Hypertension.

Dr Guo will also provide major support for the company’s efforts to enter new and emerging markets including the People’s Republic of China and the United States.

Cyclopharm Managing Direcor and CEO James McBrayer said, “We are delighted that Dr Guo has joined the Cyclopharm team as a key development executive.

“We already know Michael well as he has for a few years served Cyclopharm as a consultant and has been highly instrumental in assisting us to implement our successful expansion strategy in China.”

Dr Guo received his medical degree from Jiao tong University in Shanghai China. He went on to complete his residency in General, Orthopaedic, Brain and Thoracic Surgery at Shanghai Zha-Bei District Central Hospital in Shanghai and was later appointed Resident Staff Surgeon specialising in thoracic surgery at the same Hospital.

Dr Guo also holds a Masters of Health Information Management from the University of Sydney.

Since moving to Australia in 1989, Dr Guo has undertaken assignments for the National Health & Medical Research Council (NH&MRC) and the National E-Health Transition Authority.

Most recently Dr Guo served as the Clinical Research Scientist and Network Coordinator for Austral-Asian Severe Asthma Network at the Woolcock Institute of Medical Research where he worked with high profile respiratory medicine researchers and clinicians in Australia, New Zealand and China.

For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411

Page 1 of 2

==> picture [151 x 48] intentionally omitted <==

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700[o] C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Page 2 of 2